financetom
Business
financetom
/
Business
/
ARMOUR Residential REIT posts Q3 net income of $156.3 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ARMOUR Residential REIT posts Q3 net income of $156.3 mln
Oct 22, 2025 2:03 PM

Overview

* ARMOUR Q3 GAAP net income $156.3 mln, $1.49 per share

* Book value per common share rose 3.5% to $17.49

* Company raised $298.6 mln from common stock sale in August

Outlook

* Company did not provide specific guidance for future quarters or full year

Result Drivers

* GAINS ON MBS - Co reports $177.1 mln gain on mortgage-backed securities, contributing to net income

* CAPITAL RAISING - ARMOUR raised $298.6 mln from common stock sale in August, strengthening financial position

* BOOK VALUE INCREASE - Book value per common share rose 3.5% to $17.49, reflecting strategic portfolio management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $75.30

Distribu mln

table

Earnings

Q3 Net $38.50

Interest mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "buy."

* Wall Street's median 12-month price target for ARMOUR Residential REIT Inc ( ARR/PC ) is $18.00, about 12.8% above its October 21 closing price of $15.69

* The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dollar General Names Donny Lau CFO
Dollar General Names Donny Lau CFO
Aug 20, 2025
04:40 PM EDT, 08/20/2025 (MT Newswires) -- Dollar General ( DG ) said late Wednesday it appointed Donny Lau as chief financial officer, starting Oct. 20. Lau, who was most recently the CFO of Zaxby's Franchising, will succeed Kelly Dilts, who is leaving the company on Aug. 28. In the interim period, the company's Chief Executive, Todd Vasos, will serve...
Coty Fiscal Q4 Adjusted Loss Widens, Revenue Falls
Coty Fiscal Q4 Adjusted Loss Widens, Revenue Falls
Aug 20, 2025
04:42 PM EDT, 08/20/2025 (MT Newswires) -- Coty ( COTY ) reported fiscal Q4 adjusted net loss late Wednesday of $0.05 per diluted share, widening from a loss of $0.03 a year earlier. Analysts polled by FactSet expected adjusted earnings of $0.01 per share. Revenue for the quarter ended June 30 was $1.25 billion, down from $1.36 billion a year...
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing
Aug 20, 2025
04:43 PM EDT, 08/20/2025 (MT Newswires) -- Eben Tessari, COO, on August 18, 2025, sold 16,200 shares in Kiniksa Pharmaceuticals International ( KNSA ) for $547,141. Following the Form 4 filing with the SEC, Tessari has control over a total of 40,215 Class A ordinary shares of the company, with 40,215 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1730430/000141588925022460/xslF345X05/form4-08202025_080850.xml ...
Exclusive-CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
Exclusive-CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
Aug 20, 2025
(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email. It also will not cover Yeztugo under its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved